These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 21692942)

  • 1. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
    Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
    J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection.
    Ioannou GN; Bryson CL; Weiss NS; Boyko EJ
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):577-84. PubMed ID: 25769096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.
    Blanco F; Barreiro P; Ryan P; Vispo E; Martín-Carbonero L; Tuma P; Labarga P; Medrano J; González-Lahoz J; Soriano V
    J Viral Hepat; 2011 Jan; 18(1):11-6. PubMed ID: 20088890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
    Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
    Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver stiffness values in HIV-infected patients with isolated anti-hepatitis B core antibodies.
    Chakvetadze C; Bani-Sadr F; Lescure FX; Fontaine C; Le Pendeven C; Bonnard P; Mariot P; Soussan P; Pialoux G
    Med Mal Infect; 2013 Jun; 43(6):222-5. PubMed ID: 23597924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
    Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
    Laguno M; Milinkovic A; de Lazzari E; Murillas J; Martínez E; Blanco JL; Loncá M; Biglia A; Leon A; García M; Larrousse M; García F; Miró JM; Gatell JM; Mallolas J
    Antivir Ther; 2005; 10(3):423-9. PubMed ID: 15918333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
    Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
    J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside analogues and mitochondrial toxicity.
    Fleischer R; Boxwell D; Sherman KE
    Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients.
    Merchante N; Macías J; Ramayo E; Vergara S; García-García JA; Mira JA; Corzo JE; Gómez-Mateos JM; Lozano F; Pineda JA
    J Viral Hepat; 2006 Jul; 13(7):449-56. PubMed ID: 16792538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
    Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
    HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.